Published in Cancer Weekly, November 25th, 1996
The antigen, called CagA, is a component of Helicobacter pylori and is expected to be used in the development of diagnostic products for the detection of H. pylori infection. CagA is one of several antigens OraVax is evaluating for inclusion in its vaccines against H. pylori.
An estimated 30 percent of U.S. citizens are infected with H. pylori bacteria, with infection rates in other parts of the world...
Want to see the full article?
Welcome to NewsRx!
Learn more about a six-week, no-risk free trial of Cancer Weekly
NewsRx also is available at LexisNexis, Gale, ProQuest, Factiva, Dialog, Thomson Reuters, NewsEdge, and Dow Jones.